Patient’s Feelings After Receiving a Diagnosis of Age-related Macular Degeneration

Overview

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population of the industrialized world. AMD is a progressive degenerative disease affecting the central area of the retina, responsible for distinct vision. Vision loss arises from aberrant new vessel growth which causes the accumulation of blood or fluid within the retina's thickness and eventually leads to permanent scarring. The two major forms of AMD are exudative, or neovascular or "wet", and non-exudative, or "dry".

Vascular endothelial growth factor (VEGF) represents the key modulator of the angiogenetic process and is involved in the pathophysiology of AMD. Anti VEGF therapies are used to treat wet-AMD.

After diagnosis and explanations of the practionner, the patients and their close relatives have still frequently many questions about the intravitreal injections, the prognosis, the risk of visual impairment, etc. Few teams have studied the modalities of diagnosis announcement and the understanding of the patients on the disease course.

The aim of this study is to evaluate the feelings after the AMD diagnosis announcement as well as the understanding of the possibilities of treatment and the clinical surveillance.

Full Title of Study: “Ressenti du Patient au Moment de l’Annonce du Diagnostic de DMLA”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 1, 2018

Clinical Trial Outcome Measures

Primary Measures

  • Description of the patient’s feelings
    • Time Frame: up to 1 month after diagnosis
    • A questionnaire with a list of different feelings: anxiety, distress, relief, resigned, guilty, etc. is proposed to the patient after AMD diagnosis. they can also explain their feelings by themselves.

Secondary Measures

  • score of general satisfaction
    • Time Frame: up to 1 month after diagnosis
    • the patient will score their satisfaction on a numeric scale from 0 (not satisfied at all) to 10 (extremely satisfied)
  • score on a comprehension quiz on AMD
    • Time Frame: up to 1 month after diagnosis
  • Score on a composite score evaluating the clarity of medical explanations
    • Time Frame: up to 1 month after diagnosis
  • Score on a composite score evaluating the clarity of medical explanations
    • Time Frame: between 6 months and 1 year of follow-up
  • score of satisfaction of announcement conditions
    • Time Frame: up to 1 month after diagnosis
  • score of satisfaction of announcement conditions
    • Time Frame: between 6 months and 1 year of follow-up
  • score of satisfactions regarding the clarity of the disease course and treatment explanations
    • Time Frame: between 6 months and 1 year of follow-up
  • Score on the anxiety PHQ9 questionnaire
    • Time Frame: between 6 months and 1 year of follow-up
  • Score on the anxiety GAD7 questionnaire
    • Time Frame: between 6 months and 1 year of follow-up

Participating in This Clinical Trial

Inclusion Criteria

  • patient up to 55 years old
  • wet AMD
  • diagnostic questionnaire group: patient being announced with AMD for less than 1 month
  • disease course questionnaire group: patients treated by anti-VEGF from 6 to 12 months

Exclusion Criteria

  • dry AMD
  • patient under 55 years old
  • patient who doesn't speak French
  • patient carrying an ophtalmologic genetic disorder

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Intercommunal Creteil
  • Provider of Information About this Clinical Study
    • Principal Investigator: JoĆ«lle Marciano, Orthoptist in the ophtalmologic department of the CHI Creteil – Centre Hospitalier Intercommunal Creteil

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.